Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

Post Menopausal Osteoporosis Therapeutics Pipeline Analysis

P&S Market Research-Post Menopausal Osteoporosis Therapeutics Pipeline Analysis report

Post Menopausal Osteoporosis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 24-72 Working Hours
Report Code: LS11039
Available Format: pdf

Postmenopausal osteoporosis is a condition affecting millions of women worldwide. It is characterised by decreased bone density in women of postmenopausal age which in turn increases the fragility of bones and making them susceptible to increased risk of sudden and unexpected bone fractures. The cause of postmenopausal osteoporosis is not clearly identified, however, the decrease in bone density is directly linked to deficiency of estrogen, a natural consequence of menopause in women. Since, menopause is an inevitable part of a women’s life, postmenopausal women are at high risk of being affected with osteoporosis. Other risk factors include family history, body weight and bone structure. In osteoporosis, bone mineral density (BMD) drops down to levels below normal range, which can be measured by a bone density scan. The treatment of postmenopausal osteoporosis includes medications to treat osteoporosis specifically such as selective estrogen receptor modulator (SERM), bisphosphonates, monoclonal antibodies, calcium, Vitamin D analogues and hormone replacement therapy (HRT). In addition to the existing classes of drugs, many new drugs are under development for the treatment of postmenopausal osteoporosis.

The main growth drivers for the pipeline of postmenopausal osteoporosis therapeutics include increasing ageing women population, innovations in the osteoporosis drug development market, increasing investment on healthcare infrastructure, rising awareness and consciousness among women about the risk of postmenopausal osteoporosis.

In 2017, Radius Health, Inc. submitted a marketing authorisation application (MAA) for Abaloparatide-SC to the European Medicines Agency (EMA) for the treatment of postmenopausal women with osteoporosis. Abaloparatide is a novel synthetic peptide analog of the PTH receptor binding domain of parathyroid hormone-related protein (PTHrP), a natural hormone that can increase bone mineral density by stimulating new bone formation. In November 2016, Amgen Inc. and UCB Pharmaceuticals announced results from a Phase III study that demonstrated that romosozumab treatment in men with osteoporosis, resulted in significant bone mineral density (BMD) gains at the lumbar spine, total hip and femoral neck compared to placebo at six and 12 months. In June 2011, Synthes, Inc. and Eli Lilly and Company entered into a collaboration agreement in the domain of osteoporosis. As part of the agreement, the companies agreed to develop and license early stage molecules from Eli Lilly and Company to Synthes Inc. for use within orthopedic areas. The agreement allowed for joint development of site-specific osteoinductive products with the help of on Synthes' biomaterials combined with Eli Lilly's biologics or pharmaceuticals.

The key market players having a pipeline for postmenopausal osteoporosis include Eli Lilly and Company, Pfizer, Inc., F. Hoffman La Roche, Shire plc, Merck Sharp & Dohme Corp., GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Novartis AG, Amgen Inc., Eisai Co., Ltd., Sanofi S.A.,   Procter & Gamble Co., Radius Health, Inc., Tarsa Therapeutics, Inc., Zosano Pharma Inc., Ligand Pharmaceuticals, Alvogen Korea Co.Ltd, Nordic Bioscience A/S, CMX Research Inc., PhytoHealth Corporation, TransPharma Medical, Yuyu Pharma, Inc., Bayer AG, Deltanoid Pharmaceuticals, Hanlim Pharm. Co., Ltd., Takeda Pharmaceutical Company Ltd., Asahi Kasei Pharma Corporation, Ono Pharma USA Inc., Nastech Pharmaceutical Company, Inc., Azelon Pharmaceuticals, Bionovo, and Zelos Therapeutics.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

3250
Group License

Group License authorizes access of the publication upto 5 users.

4000
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

5500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

7750
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment